skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Development and Testing of a 212Pb/212Bi Peptide for Targeting Metastatic Melanoma

Abstract

The purpose of this project is to develop a new radiolabeled peptide for imaging and treating metastatic melanoma. The immunoconjugate consists of a receptor-specific peptide that targets melanoma cells. The beta-emitter lead-212 (half-life = 10.4 hours) is linked by coordination chemistry to the peptide. After injection, the peptide targets melanoma receptors on the surfaces of melanoma cells. Lead-212 decays to the alpha-emitter bismuth-212 (half-life = 60 minutes). Alpha-particles that hit melanoma cell nuclei are likely to kill the melanoma cell. For cancer cell imaging, the lead-212 is replaced by lead-203 (half-life = 52 hours). Lead-203 emits 279 keV photons (80.1% abundance) that can be imaged and measured for biodistribution analysis, cancer imaging, and quantitative dosimetry.

Authors:
Publication Date:
Research Org.:
Pacific Northwest National Lab. (PNNL), Richland, WA (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1054055
Report Number(s):
PNNL-21943
NN4010021
DOE Contract Number:  
AC05-76RL01830
Resource Type:
Technical Report
Country of Publication:
United States
Language:
English

Citation Formats

Fisher, Darrell R. Development and Testing of a 212Pb/212Bi Peptide for Targeting Metastatic Melanoma. United States: N. p., 2012. Web. doi:10.2172/1054055.
Fisher, Darrell R. Development and Testing of a 212Pb/212Bi Peptide for Targeting Metastatic Melanoma. United States. doi:10.2172/1054055.
Fisher, Darrell R. Thu . "Development and Testing of a 212Pb/212Bi Peptide for Targeting Metastatic Melanoma". United States. doi:10.2172/1054055. https://www.osti.gov/servlets/purl/1054055.
@article{osti_1054055,
title = {Development and Testing of a 212Pb/212Bi Peptide for Targeting Metastatic Melanoma},
author = {Fisher, Darrell R.},
abstractNote = {The purpose of this project is to develop a new radiolabeled peptide for imaging and treating metastatic melanoma. The immunoconjugate consists of a receptor-specific peptide that targets melanoma cells. The beta-emitter lead-212 (half-life = 10.4 hours) is linked by coordination chemistry to the peptide. After injection, the peptide targets melanoma receptors on the surfaces of melanoma cells. Lead-212 decays to the alpha-emitter bismuth-212 (half-life = 60 minutes). Alpha-particles that hit melanoma cell nuclei are likely to kill the melanoma cell. For cancer cell imaging, the lead-212 is replaced by lead-203 (half-life = 52 hours). Lead-203 emits 279 keV photons (80.1% abundance) that can be imaged and measured for biodistribution analysis, cancer imaging, and quantitative dosimetry.},
doi = {10.2172/1054055},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2012},
month = {10}
}

Technical Report:

Save / Share: